A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Rosiglitazone in Combination with Glimepiride Compared to Glimepiride Plus Placebo for 24 Weeks in Subjects with Type 2 DiabetesMellitus Who are Inadequately Controlled on Non-TZD Oral Monotherapy
Diabetes Mellitus, Type 2
Phase 3
An analysis-ready dataset is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013